Month: March 2026

JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) — Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Inzymes ApS (“Inzymes”), a Denmark-based enzyme company specializing in the development, scale-up, and commercialization of enzymes for sustainable food and beverage applications, today announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme used in cheese production and dairy processing, following the successful completion of final development activities under the companies’ collaboration agreement. Completion of these development activities represents a contractual...

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) announced today that Fancamp has received notice from The Canadian Chrome Company Inc. (formerly KWG Resources Inc.) (“CCC”) of the exercise of its one-time option to extend the maturity date of the secured convertible promissory note dated September 1, 2022 issued by CCC in favour of Fancamp. The maturity date of the secured convertible promissory note will be extended from September 1, 2026 to August 31, 2027, provided there is no event of default under the secured convertible promissory note on or before September 1, 2026. About Secured Convertible Promissory Note As previously announced, Fancamp agreed to sell its beneficial interests in the Koper Lake-McFaulds mining claims located...

LONDON, March 02, 2026 (GLOBE NEWSWIRE) — Navigator Holdings Ltd. (“Navigator Gas” or the “Company”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, is pleased to announce that today, its subsidiaries, Navigator Parsec L.L.C. and Navigator Pleione L.L.C. (the “Borrowers”), entered into a senior secured pre- and post-delivery term loan (the “Facility Agreement”) with ABN AMRO Bank N.V., Crédit Agricole Corporate & Investment Bank and Nordea Bank Abp, filial i Norge (together, the “Lenders”), pursuant to which the Lenders have agreed to make available to the Borrowers up to $133,770,000, subject to the terms and conditions set out in the Facility Agreement. The loan will be used to finance up to 65% of the Borrowers’ payments of the pre-delivery and delivery instalments...

Transaction sharpens focus on higher-margin core categoriesHain Celestial Completes Sale of North American Snacks BusinessProceeds from the transaction will be used to reduce debt, strengthening the company’s financial position and leverage profile.HOBOKEN, N.J., March 02, 2026 (GLOBE NEWSWIRE) — Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today announced that it has completed the previously announced sale of its North American Snacks business, including Garden Veggie Snacks™, Terra® chips and Garden of Eatin’® snacks, to Snackruptors Inc., a Canadian, family-owned snacks manufacturer. Proceeds from the transaction will be used to reduce debt, strengthening the company’s financial position and...

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company’s royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the value of this innovation. This momentum is expected to continue into 2026 and beyond, as modalities, therapeutic areas and deal structures out of...

Phase 1 trial evaluating GTB-3650 TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 remains on track to initiate mid-2026 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, March 02, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager TriKE® platform, today announced full year 2025 financial results for the period ended December 31, 2025. “2026 looks...

Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal. Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD. Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders.WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, PhD, as its Chief Medical Innovation Officer. Prof. Brown, is a psychiatrist, neurologist, and neuroscientist who studies the underlying mechanisms...

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) — Westhaven Gold Corp. (TSX-V: WHN) (OTCQB: WTHVF) (“Westhaven” or the “Company”) announces the appointments of Allison Rippin Armstrong as Vice President, Indigenous and Community Relations, and Pamela O’Hara as Vice President, Permitting and Government Affairs, effective April 1, 2026. Ken Armstrong, President and Chief Executive Officer of Westhaven, commented, “I am pleased to welcome Allison and Pamela to Westhaven at a defining stage for the Company. These appointments reflect the deliberate steps Westhaven and Dundee Corporation are taking to assemble the expertise and leadership needed to responsibly advance the Shovelnose gold project in southern British Columbia. Allison brings extensive experience working alongside Indigenous communities and navigating...